Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F19%3A00124587" target="_blank" >RIV/00216224:14110/19:00124587 - isvavai.cz</a>

  • Výsledek na webu

    <a href="https://journalretinavitreous.biomedcentral.com/articles/10.1186/s40942-019-0179-6" target="_blank" >https://journalretinavitreous.biomedcentral.com/articles/10.1186/s40942-019-0179-6</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1186/s40942-019-0179-6" target="_blank" >10.1186/s40942-019-0179-6</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy

  • Popis výsledku v původním jazyce

    BackgroundElevated serum vascular endothelial growth factor (VEGF) levels are associated with diabetic retinopathy (DR). Serum VEGF levels correlate with vitreous levels. Neuroretinal changes occur even before the appearance of vascular signs in DR. Role of VEGF as a biomarker for DR has not been assessed. Serum VEGF as a biomarker for severity of DR, was evaluated for the first time.MethodsConsecutive cases of type 2 diabetes mellitus [without DR, (no DR, n=38); non-proliferative DR, (NPDR, n=38); proliferative DR, (PDR, n=40)] and healthy controls (n=40) were included. Serum VEGF was measured using enzyme linked immunosorbent assay. Accuracy of VEGF as a biomarker for severity of retinopathy was measured using the area under the receiver operator characteristic (ROC) curve.ResultsSerum VEGF levels in controls, No DR, NPDR and PDR groups showed significant incremental trend from 138.96 +/- 63.37 pg/ml (controls) to 457.18 +/- 165.69 pg/ml (PDR) (F=48.47; p&lt;0.001). Serum VEGF levels were observed to be significantly elevated even before DR had set in clinically. ROC for serum VEGF levels was significant in discriminating between the cases and the controls and had good accuracy in discerning between subjects with and without retinopathy. The area under curve (AUC +/- SE) for discrimination was significant: (a) cases and controls (n=156): AUC=0.858 +/- 0.029, p&lt;0.001; (b) DR (NPDR+PDR) and No DR (n=116): AUC=0.791 +/- 0.044, p&lt;0.001; and (c) NPDR and PDR (n=78): AUC=0.761 +/- 0.056, p&lt;0.001, with over 90% projected sensitivity and specificity at various cut off values.Conclusion Serum VEGF level is a simple, effective laboratory investigative test in predicting the onset of DR in eyes showing no evidence of DR and serves as a reliable biomolecular biomarker for severity of DR.

  • Název v anglickém jazyce

    Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy

  • Popis výsledku anglicky

    BackgroundElevated serum vascular endothelial growth factor (VEGF) levels are associated with diabetic retinopathy (DR). Serum VEGF levels correlate with vitreous levels. Neuroretinal changes occur even before the appearance of vascular signs in DR. Role of VEGF as a biomarker for DR has not been assessed. Serum VEGF as a biomarker for severity of DR, was evaluated for the first time.MethodsConsecutive cases of type 2 diabetes mellitus [without DR, (no DR, n=38); non-proliferative DR, (NPDR, n=38); proliferative DR, (PDR, n=40)] and healthy controls (n=40) were included. Serum VEGF was measured using enzyme linked immunosorbent assay. Accuracy of VEGF as a biomarker for severity of retinopathy was measured using the area under the receiver operator characteristic (ROC) curve.ResultsSerum VEGF levels in controls, No DR, NPDR and PDR groups showed significant incremental trend from 138.96 +/- 63.37 pg/ml (controls) to 457.18 +/- 165.69 pg/ml (PDR) (F=48.47; p&lt;0.001). Serum VEGF levels were observed to be significantly elevated even before DR had set in clinically. ROC for serum VEGF levels was significant in discriminating between the cases and the controls and had good accuracy in discerning between subjects with and without retinopathy. The area under curve (AUC +/- SE) for discrimination was significant: (a) cases and controls (n=156): AUC=0.858 +/- 0.029, p&lt;0.001; (b) DR (NPDR+PDR) and No DR (n=116): AUC=0.791 +/- 0.044, p&lt;0.001; and (c) NPDR and PDR (n=78): AUC=0.761 +/- 0.056, p&lt;0.001, with over 90% projected sensitivity and specificity at various cut off values.Conclusion Serum VEGF level is a simple, effective laboratory investigative test in predicting the onset of DR in eyes showing no evidence of DR and serves as a reliable biomolecular biomarker for severity of DR.

Klasifikace

  • Druh

    J<sub>imp</sub> - Článek v periodiku v databázi Web of Science

  • CEP obor

  • OECD FORD obor

    30212 - Surgery

Návaznosti výsledku

  • Projekt

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2019

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    INTERNATIONAL JOURNAL OF RETINA AND VITREOUS

  • ISSN

    2056-9920

  • e-ISSN

    2056-9920

  • Svazek periodika

    5

  • Číslo periodika v rámci svazku

    1

  • Stát vydavatele periodika

    GB - Spojené království Velké Británie a Severního Irska

  • Počet stran výsledku

    6

  • Strana od-do

    1-6

  • Kód UT WoS článku

    000693102600023

  • EID výsledku v databázi Scopus

    2-s2.0-85073051045